PDCD1LG2 and non-small cell lung carcinoma: Nivolumab (Opdivo), a human IgG4 monoclonal antibody that binds to the PD-1 receptor and inhibits PD-1 receptor interaction with PD-L1 and PD-L2, is FDA approved for metastatic squamous and nonsquamous NSCLC with disease progression on or after platinum-based chemotherapy.